Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 6
Submit an article Journal homepage
2,733
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Jan A. Burgera Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
,
Tadeusz Robakb Medical University of Lodz, Copernicus Memorial Hospital, Lodz, PolandORCID Iconhttps://orcid.org/0000-0002-3411-6357View further author information
ORCID Icon,
Fatih Demirkanc Dokuz Eylul University, Izmir, TurkeyView further author information
,
Osnat Baireyd Rabin Medical Center, Petah Tikva, IsraelView further author information
,
Carol Morenoe Hospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona, Barcelona, SpainView further author information
,
David Simpsonf BeiGene, San Mateo, CA, USAView further author information
,
Talha Munirg Department of Haematology, St. James’s Hospital, Leeds, United KingdomView further author information
,
Don A. Stevensh Norton Cancer Institute, Louisville, KY, USAView further author information
,
Sandra Daii Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information
,
Leo W. K. Cheungi Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information
,
Kevin Kweii Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information
,
Indu Lali Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information
,
Emily Hsui Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USAView further author information
,
Thomas J. Kippsj University of California San Diego, Moores Cancer Center, La Jolla, CA, USAView further author information
&
Alessandra Tedeschik ASST Grande Ospedale Metropolitano Niguarda, Milan, ItalyView further author information
 show all
Pages 1375-1386 | Received 14 Sep 2021, Accepted 13 Dec 2021, Published online: 11 Jan 2022

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Estella Matutes & Aaron Polliack. (2022) Is ibrutinib the gold standard for therapy – naive elderly patients with CLL?. Leukemia & Lymphoma 63:6, pages 1265-1266.
Read now

Articles from other publishers (2)

Andrea Messori. (2022) Long‐term progression‐free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons. European Journal of Haematology 110:1, pages 60-66.
Crossref
Nadine Kutsch, Anna Maria Fink & Kirsten Fischer. (2022) Management of front line chronic lymphocytic leukemia. American Journal of Hematology 97:S2.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.